Ocrelizumab Proven Effective In Multiple Sclerosis Treatment for Primary Progressive MS (PPMS)

Successful clinical trial results by Bay Area researchers was released Thursday on a new drug that shows promise to become the first drug to treat a devastating progressive form of multiple sclerosis (MS). Roche Holding AG’s Genetech unit announced that the experimental drug ocrelizumab proved effective in three studies against MS, reports The Wall Street Journal. The findings in the late-phase trials of ocrelizumab find that the drug greatly reduces symptoms for progressive MS as well as a more common form of the degenerative disease, known as relapsing and remitting multiple sclerosis, which affects nearly 85 percent of MS patients.

Continue Reading